Skip to content
About Us
Technology
Pipelines
Team
News
中文
2026年7月2日
Categories
News
Multitude Therapeutics Announces Encouraging Interim Phase I Results from Ongoing First-in-Human Study Evaluating its CDH17-directed Antibody-Drug-Conjugate, AMT-676, in patients with advanced CRC at the 2026 ESMO GI Cancer Congress
2026-07-02
AMT-676 is a p…
Read More →
Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors
2026-07-02
Download Full …
Read More →
